Article

Quantifying target antigen-dependent CAR T-cell performance against AML

2024-12-16

Abstract excerpt

Chimeric Antigen Receptor (CAR) T-cell therapy has transformed cancer immunotherapy by genetically engineering T-cells to target tumor antigens. Acute myeloid leukemia (AML) presents unique challenges due to resistance mechanisms, especially in patients with TP53 loss mutations. The complex dynamics of CAR T-cell expansion remain poorly understood. The field lacks validated quantitative frameworks to systematicall...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c3f7c2e-6cda-5418-918a-cdb8a1b2118b
DOI: 10.1101/2024.12.16.628628

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quantifying target antigen-dependent CAR T-cell performance against AMLDOI 10.1101/2024.12.16.628628Read

Mechanisms of Resistance to CAR-T cell Immunotherapy: Insights from a Mathematical ModelSemantic proximity Read

Deconvolution of clinical variance in CAR-T cell pharmacology and responseSemantic proximity Read

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic DifferentiationSemantic proximity Read

Healthy B cells: allies or adversaries of CAR-T cell immunotherapy?Semantic proximity Read

Antigen experience history directs distinct functional states of CD8+ CAR T cells during the anti-leukemia responseSemantic proximity Read

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read

Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictionsSemantic proximity Read

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics Via Phenotypic DifferentiationSemantic proximity Read

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapySemantic proximity Read

A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapySemantic proximity Read

Toxicity Management in CAR T cell therapy for B-ALL: Mathematical modelling as a new avenue for improvementSemantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read